Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.

Keane, Holly; Huilgol, Yash S; Shieh, Yiwey; Tice, Jeffrey A; Belkora, Jeff; Sepucha, Karen; Shibley, W Patrick; Wang, Tianyi; Che, Mandy; Goodman, Deborah; Ozanne, Elissa; Fiscalini, Allison Stover; Esserman, Laura J

Keane, Holly; Huilgol, Yash S; Shieh, Yiwey; Tice, Jeffrey A; Belkora, Jeff; Sepucha, Karen; Shibley, W Patrick; Wang, Tianyi; Che, Mandy; Goodman, Deborah; Ozanne, Elissa; Fiscalini, Allison Stover; Esserman, Laura J.

Afiliação

Keane H; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Huilgol YS; Peter MacCallum Cancer Centre, Melbourne, Australia.
Shieh Y; School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Tice JA; Joint Medical Program, School of Public Health, University of California, Berkeley, Berkeley, CA, USA.
Belkora J; School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Sepucha K; School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Shibley WP; Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA, USA.
Wang T; Health Decision Sciences Center, Massachusetts General Hospital, Boston, MA, USA.
Che M; School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Goodman D; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Ozanne E; Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
Fiscalini AS; Department of Epidemiology, University of California, Irvine, Irvine, CA, USA.
Esserman LJ; Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.

NPJ Breast Cancer ; 7(1): 78, 2021 Jun 17.

Article em En | MEDLINE | ID: mdl-34140528

ABSTRACT

ABSTRACT

Breast cancer risk reduction has been validated by large-scale clinical trials, but uptake remains low. A risk communication tool could provide personalized risk-reduction information for high-risk women. A low-literacy-friendly, visual, and personalized tool was designed as part of the Women Informed to Screen Depending On Measures of risk (WISDOM) study. The tool integrates genetic, polygenic, and lifestyle factors, and quantifies the risk-reduction from undertaking medication and lifestyle interventions. The development and design process utilized feedback from clinicians, decision-making scientists, software engineers, and patient advocates. We piloted the tool with 17 study participants, collecting quantitative and qualitative feedback. Overall, participants felt they better understood their personalized breast cancer risk, were motivated to reduce their risk, and considered lifestyle interventions. The tool will be used to evaluate whether risk-based screening leads to more informed decisions and higher uptake of risk-reduction interventions among those most likely to benefit.

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google